Results 151 to 160 of about 56,147 (276)
Journal of Neuropsychology, EarlyView.Abstract Dementia constitutes one of the most widespread neurological disorders, representing an important health concern due to its increasing prevalence. Among the various types of dementia, Alzheimer's disease (AD) is the most common in the elderly, characterized by episodic memory impairment and also a decline in executive functions. Mild cognitive
Luis Heredia +3 more
wiley +1 more source
The Effect of Deep Brain Stimulation on Sleep and Cognition in Patients With Parkinson's Disease
Journal of Sleep Research, EarlyView.ABSTRACT Sleep–wake disturbances and cognitive decline are among the most common nonmotor symptoms of Parkinson's disease (PD). Deep brain stimulation (DBS) can successfully alleviate motor symptoms. However, the impact on sleep–wake disturbances and cognitive decline, and their interaction, is yet unclear.
Monique E. H. Valk‐Geuke +5 more
wiley +1 more source
Talking therapies for anxiety and depression in people affected by dementia: A scoping meta‐review
Psychology and Psychotherapy: Theory, Research and Practice, EarlyView.Abstract Background Symptoms of anxiety and depression are common in people affected by dementia (people with dementia and family carers). There are many reviews of psychological interventions to reduce stress and distress in people with dementia and family carers, but little cross‐fertilisation with the evidence base underpinning NHS Talking Therapies
Georgina Charlesworth +2 more
wiley +1 more source
Immune involvement in neuropsychiatric disorders: Insights from single‐cell transcriptomic studies
Psychiatry and Clinical Neurosciences, EarlyView.Neuropsychiatric disorders pose profound challenges to both research and treatment, largely due to their clinical heterogeneity and the limited understanding of their underlying biological mechanisms. While bulk RNA sequencing (bulk RNA‐seq) has been widely used to study gene expression, it cannot resolve cell‐type‐specific signals or detect rare ...
Tsutomu Takeda +4 more
wiley +1 more source
Cost‐effectiveness and impact at scale of collaborative care and lecanemab for Alzheimer's disease
Alzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 1, March 2026.Abstract INTRODUCTION Advancements in disease‐modifying therapies and collaborative dementia care programs have created opportunities to transform care for people with Alzheimer's disease. METHODS We modeled people aged 71 across three scenarios: 18 months of lecanemab, collaborative care, and combined interventions.
Kelly J. Atkins +2 more
wiley +1 more source
Targeting brain, body and heart for cognitive health and dementia prevention [PDF]
This report looks into the current research regarding dementia and Alzheimer\u27s disease prevention and offers ideas for possible future solutions. Prevention of dementia is the ultimate aim of a large, albeit under resourced, international ...
Elodie O', Maree Farrow
core
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 751-762, March 2026.Hypertension is a known modifiable risk factor for Alzheimer’s disease and related dementia (ADRD). However, it is unknown how variance in hypertension control, antihypertensive medications, and social determinants of health, such as social deprivation index (SDI), influence the risk of developing ADRD.
Eissa A. Jafari +6 more
wiley +1 more source
Spatially resolved molecular signatures of Lewy body dementia. [PDF]
Acta NeuropatholJin Y +16 more
europepmc +1 more source
Is there a preference for PET or SPECT brain imaging in diagnosing dementia? The views of people with dementia, carers, and healthy controls [PDF]
, 2016 Cam Donaldson +10 more
core +1 more source